Introduction to the KRAS G12C mutated lung cancer targeted drug sotoraxib

Sotorasib, an innovative oral targeted drug targeting KRAS G12C gene mutation, is gradually becoming a new star in the treatment of non-small cell lung cancer (NSCLC). KRASgene mutations are extremely common in cancer, especially in NSCLC. KRAS G12C mutations account for as high as 13%. KRAS mutations have long been regarded as "undruggable" difficulties, and the advent of sotorasib has undoubtedly brought a revolutionary breakthrough in cancer treatment.

In 2021, sotorasiib was approved by the FDA in the United States, becoming the first therapeutic drug that is effective for patients with advanced KRAS G12C mutationNSCLC after failure of at least one systemic therapy. Its unique feature is that it can irreversibly bind to KRAS G12C mutated protein and precisely block signaling pathways, thereby effectively inhibiting the crazy proliferation and spread of cancer cells. This highly targeted mechanism of action allows sotorasiib to exhibit excellent therapeutic effects in KRAS G12C mutation-positive patients.

Clinical trial data further confirmed the potential of sotoraxib. It not only performs well in terms of effectiveness and disease control rate, and can significantly extend the survival period of patients, but also shows good tolerability, bringing new treatment hope to many patients. However, any drug has its two sides, and sotorasiib is no exception. Side effects such as diarrhea, fatigue, nausea, and elevated transaminases are something that patients need to pay close attention to during use. To ensure the safety of treatment, it is crucial to regularly monitor liver function and promptly detect and deal with potential hepatotoxicity.

Faced with the problem of drug resistance that may arise after long-term treatment, scientific researchers are actively exploring the combined application of sotoraxib with other targeted drugs or immunotherapy in order to find more effective solutions. Although sotoracib has not yet been officially launched in China, patients can already obtain it through overseas channels. With the continuous accumulation of clinical data, we have reason to believe that sotorasibu will continue to expand its scope of indications and bring hope to more cancer patients.